On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative product, GB18.

May 19 is designated as World Inflammatory Bowel Disease (IBD) Day, aimed at raising public awareness of IBD patients and improving their quality of life and medical care.

When global pharmaceutical companies or health sector enterprises search for a Chinese biological products factory, one name consistently stands out: Kexing Biopharm.

Biopharmaceuticals, also known as biologics, have redefined the landscape of modern medicine.

The biopharmaceutical industry is undergoing a transformative era, driven by cutting-edge research, technological advancements, and an increasing demand for novel therapies.

Synthetic biology is an emerging interdisciplinary field that integrates knowledge and techniques from biology, genomics, engineering, and informatics.

In the field of bioengineering, protein design has always been a challenging task. With the rapid development of artificial intelligence (AI) technology, especially the breakthroughs in deep learning algorithms, AI-driven protein design is sparking a revolution.

In recent years, China has been making significant strides in the field of biotechnology, positioning itself as a potential global leader in the export of biological products.